Impact of Coenzyme Q10 and Selenium on Seminal Fluid and Semen Antioxidant Status
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03834831 |
Recruitment Status :
Completed
First Posted : February 8, 2019
Last Update Posted : March 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Male Infertility | Dietary Supplement: Coenzyme Q10 Dietary Supplement: Selenium | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Parallel Assignment |
Masking: | None (Open Label) |
Masking Description: | Open Label |
Primary Purpose: | Treatment |
Official Title: | Impact of Coenzyme Q10 and Selenium on Seminal Fluid Parameters and Antioxidant Status in Men With Idiopathic Infertility |
Actual Study Start Date : | June 1, 2018 |
Actual Primary Completion Date : | October 31, 2018 |
Actual Study Completion Date : | January 10, 2019 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Coenzyme Q10
Coenzyme Q10 200mg/day for 3 months
|
Dietary Supplement: Coenzyme Q10
Coenzyme Q10 |
Active Comparator: Selenium
Selenium mcg/day for 3 months
|
Dietary Supplement: Selenium
Selenium |
- Semen volume (WHO 2010 guidelines) [ Time Frame: 3 months ]Semen volume in ml
- Sperm concentration in semen (WHO 2010 guidelines) [ Time Frame: 3 months ]Sperm concentration in million/ml
- Sperm motility in semen (WHO 2010 guidelines) [ Time Frame: 3 months ]Sperm motility (%)
- Sperm morphology in semen (WHO 2010 guidelines) [ Time Frame: 3 months ]Normal sperm morphology (%)
- Seminal plasma TAC (Colorimetric assays) [ Time Frame: 3 months ]Seminal plasma total antioxidant capacity in mmol/ml
- Seminal plasma CAT (Colorimetric assays) [ Time Frame: 3 months ]Seminal plasma catalase in U/ml
- Seminal plasma SOD (Colorimetric assays) [ Time Frame: 3 months ]Superoxide dismutase in U/ml
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Male infertility |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- History of infertility of at least 12 months despite regular unprotected intercourse.
- Oligoasthenoteratospermia was diagnosed by semen analysis showing abnormal sperm concentration (<15 million/ml), progressive motility (<32%), total motility (<40%) and morphology (<30% WHO criteria) as defined by WHO manual for semen analysis 2010
Exclusion Criteria:
- Azoospermia,
- Varicocele,
- Genital tract infection,
- Cryptorchidism,
- Testicular trauma or scrotal surgery,
- Endocrine disorder,
- Systemic illness,
- Smoking
- The presence of female factor
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03834831
Iraq | |
Fertility Unit, Babyl | |
Hilla, Iraq, 00964 |
Principal Investigator: | Ahmed T Alahmar | University of Sumer, Iraq |
Responsible Party: | Dr. Ahmed T Alahmar, Principal Investigator, University of Sumer |
ClinicalTrials.gov Identifier: | NCT03834831 |
Other Study ID Numbers: |
EC/2018/8866 |
First Posted: | February 8, 2019 Key Record Dates |
Last Update Posted: | March 14, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Patients data are anonymous and in hold with the principal investigator |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Male infertility Coenzyme Q10 Selenium Antioxidants |
Infertility Infertility, Male Genital Diseases Urogenital Diseases Genital Diseases, Male Male Urogenital Diseases Selenium Ubiquinone |
Coenzyme Q10 Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Trace Elements Micronutrients Vitamins |